Navidea biopharmaceuticals files appeal in crg case

Dublin, ohio--( business wire )--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on november 29, 2022, navidea and its majority-owned subsidiary macrophage therapeutics, inc. filed an appeal of the judgment by the district court of harris county, texas in case no. 2018-24442-151; capital royalty partners ii, l.p. et al. v. navidea biopharmaceuticals, inc. and macrophage therapeutics, inc., with the 14th court of appeals of texas for review by the appellate court.
NAVB Ratings Summary
NAVB Quant Ranking